At the time of writing, Resmed Inc [RMD] stock is trading at $222.30, down -0.69%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The RMD shares have gain 0.46% over the last week, with a monthly amount drifted -4.63%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Resmed Inc [NYSE: RMD] stock has seen the most recent analyst activity on March 19, 2025, when Morgan Stanley initiated its Overweight rating and assigned the stock a price target of $280. On January 16, 2025, Goldman initiated with a Buy rating. Piper Sandler started tracking the stock assigning a Neutral rating and suggested a price target of $252 on January 10, 2025. Stifel initiated its recommendation with a Hold and recommended $250 as its price target on December 13, 2024. Robert W. Baird started tracking with a Outperform rating for this stock on September 24, 2024, and assigned it a price target of $280. In a note dated September 18, 2024, Wolfe Research downgraded an Underperform rating on this stock but restated the target price of $180.
For the past year, the stock price of Resmed Inc fluctuated between $172.19 and $263.05. Currently, Wall Street analysts expect the stock to reach $250 within the next 12 months. Resmed Inc [NYSE: RMD] shares were valued at $222.30 at the most recent close of the market. An investor can expect a potential return of 12.46% based on the average RMD price forecast.
Analyzing the RMD fundamentals
According to Resmed Inc [NYSE:RMD], the company’s sales were 4.93B for trailing twelve months, which represents an 10.26% jump. Gross Profit Margin for this corporation currently stands at 0.58% with Operating Profit Margin at 0.32%, Pretax Profit Margin comes in at 0.31%, and Net Profit Margin reading is 0.25%. To continue investigating profitability, this company’s Return on Assets is posted at 0.17, Equity is 0.25 and Total Capital is 0.25. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.16.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 220.14 points at the first support level, and at 217.98 for the second support level. However, for the 1st resistance point, the stock is sitting at 223.78, and for the 2nd resistance point, it is at 225.25.
Ratios To Look Out For
It is important to note that Resmed Inc [NYSE:RMD] has a current ratio of 3.33. As well, the Quick Ratio is 2.29, while the Cash Ratio is 0.61. Considering the valuation of this stock, the price to sales ratio is 6.63, the price to book ratio is 6.21 and price to earnings (TTM) ratio is 26.26.
Transactions by insiders
Recent insider trading involved Rider Michael J, Officer, that happened on Apr 01 ’25 when 64.0 shares were purchased. Chief Financial Officer, Sandercock Brett completed a deal on Mar 10 ’25 to sell 1000.0 shares. Meanwhile, Chief Commercial Officer, SaaS Ghoshal Kaushik sold 9745.0 shares on Mar 10 ’25.
